title: Extended resections of liver metastases from colorectal cancer.
abstract: BACKGROUND
  Indications for resection of liver metastases from colorectal cancer and surgical strategies are still under debate.
  
  
  METHODS
  We have retrospectively reviewed the outcome of 660 patients after 685 liver resections for metastases of colorectal cancer in our institution from 1988 to 2004. All surviving patients have a minimum follow-up period of 1 year. The longest follow-up in these patients is 16 years. Three different time periods of 5 to 6 years each were analyzed.
  
  
  RESULTS
  The 30- and 60-day mortality rates were 1.5% (n = 10) and 2.2 % (n = 15), respectively. The rate of formally curative (R0) resections was 84%. Five-year survival rates in all patients and in patients after R0 resection were 37% and 42%, respectively. If only resections from 1999 to 2004 were considered, 5-year survival in patients after R0 resection was 50%. In a multivariate analysis, surgical radicality, ligamental lymph node involvement, number of liver metastases, and time period, in which the liver resection had been performed, were independent prognostic parameters.
  
  
  CONCLUSIONS
  Outcome after liver resection for metastases from colorectal cancer has constantly improved. A formally curative resection is the most relevant prognostic parameter. Number of liver metastases and, in the few patients concerned, lymph node infiltration of the hepatoduodenal ligament, were further prognostic parameters.
authors.affiliation: Department of General, Visceral and Transplantation Surgery, Charité Campus Virchow-Klinikum, University Medicine, Augustenburger Platz 1, 13353, Berlin, Germany. sven.jonas@charite.de
authors.forename: S
authors.initials: S
authors.lastname: Jonas
authors.forename: A
authors.initials: A
authors.lastname: Thelen
authors.forename: C
authors.initials: C
authors.lastname: Benckert
authors.forename: A
authors.initials: A
authors.lastname: Spinelli
authors.forename: S
authors.initials: S
authors.lastname: Sammain
authors.forename: U
authors.initials: U
authors.lastname: Neumann
authors.forename: B
authors.initials: B
authors.lastname: Rudolph
authors.forename: P
authors.initials: P
authors.lastname: Neuhaus
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017115:Catheter Ablation; D016009:Chi-Square Distribution; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D018709:Statistics, Nonparametric; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents